The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail


MorphoSys AGEU/1/21/1570/001

Main Information

Trade NameMinjuvi
Active SubstancesTafasitamab
Dosage FormPowder for concentrate for solution for infusion
Licence HolderMorphoSys AG
Licence NumberEU/1/21/1570/001

Group Information

ATC CodeL01XC Monoclonal antibodies
L01XC35 Tafasitamab


License statusAuthorised
Licence Issued26/08/2021
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back